New Research Highlights Urgent Need for Early Detection of Heart Failure in Patients with Asymptomatic Atrial Fibrillation

New Research Highlights Urgent Need for Early Detection of Heart Failure in Patients with Asymptomatic Atrial Fibrillation

(IN BRIEF) New data presented at EHRA 2026 show that individuals with atrial fibrillation detected through screening face a threefold higher risk of developing heart failure compared with those without AF, with a risk level similar to patients with known AF. Based on the Swedish STROKESTOP studies, heart failure often develops within months of AF detection, emphasizing that asymptomatic AF is not benign. The findings support the importance of early detection and monitoring of both AF and heart failure to improve patient outcomes.

(PRESS RELEASE) SOPHIA ANTIPOLIS, 13-Apr-2026 — /EuropaWire/ — New research presented at EHRA 2026 highlights a significant link between atrial fibrillation (AF) detected through screening and the subsequent development of heart failure (HF), suggesting that even asymptomatic cases of AF carry substantial clinical risk.

The findings were shared during the annual congress of the European Heart Rhythm Association, part of the European Society of Cardiology, and are based on analyses of the Swedish STROKESTOP and STROKESTOP II studies. These large-scale studies investigated individuals aged 75 to 76 years who were either invited to undergo ECG-based screening for AF or assigned to a control group.

Atrial fibrillation is a widespread condition affecting nearly 38 million people globally, with projections indicating a significant increase in prevalence in the coming decades. While stroke is widely recognized as a major complication of AF, heart failure is also a frequent and serious outcome that contributes significantly to mortality.

According to Gina Sado of Danderyd Hospital in Stockholm, AF and HF are closely interconnected conditions that can accelerate each other’s progression. While the relationship between heart failure and clinically diagnosed AF has been well established, less was previously known about the risks faced by individuals whose AF is identified through screening rather than symptoms.

The analysis examined long-term outcomes over median follow-up periods of 6.9 years for STROKESTOP and 5.1 years for STROKESTOP II. In the STROKESTOP cohort, 252 participants were newly diagnosed with AF through screening, and 57 of these individuals (23%) developed heart failure during follow-up. In STROKESTOP II, 152 participants were identified with AF, with 31 (20%) subsequently diagnosed with HF.

Statistical analysis revealed that individuals with screening-detected AF had approximately a threefold higher risk of developing heart failure compared with those without AF. Importantly, their risk was similar to that observed in patients with previously diagnosed AF. These patterns were consistent across both study populations.

A notable finding was the timing of heart failure diagnosis, which frequently occurred within six months of AF detection. This early onset underscores the importance of prompt clinical evaluation and monitoring following the identification of atrial fibrillation, even in individuals who do not exhibit symptoms.

The results indicate that AF identified through screening should not be considered a low-risk or incidental finding. Instead, it represents a clinically meaningful condition requiring careful management and follow-up. The research highlights the need for early detection strategies targeting both atrial fibrillation and heart failure to improve patient outcomes and reduce the burden of cardiovascular disease.

SOURCE: European Society of Cardiology (ESC)